Search results
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
The early use of remdesivir in outpatients with Covid-19 who...
- Free Full Text
We conducted a double-blind, randomized, placebo-controlled...
- Editorial Jan 27, 2022 The Goldilocks Time for Remdesivir — Is Any Indication Just Right E.L. Heil and S. Kottilil
Gottlieb et al. conducted a clinical trial — the results of...
- Original Article Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma H. Tilly and Others
Diffuse large B-cell lymphoma (DLBCL) is typically treated...
- Original Article Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis S.R. Ytterberg and Others
Tofacitinib is a targeted synthetic DMARD that selectively...
- Interactive Medical Case Up in The Air J.V. Loewenthal and Others
Case 3-2022: A 14-Year-Old Boy with Fever, Joint Pain, and...
- Editorial The Price of Freedom From Tricuspid Regurgitation J. Chikwe and M. Gaudino
From the Department of Cardiac Surgery, Smidt Heart...
- Perspective Please Don't Keep Me A. Drutchas
Early Remdesivir to Prevent Progression to Severe Covid-19...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Chcieliśmy się dowiedzieć, czy remdesiwir jest skuteczny w leczeniu chorych na COVID-19 i czy jego stosowanie wiąże się z występowaniem niepożądanych skutków, w porównaniu z placebo lub standardową opieką.
We reported the preliminary results of the DisCoVeRy trial regarding the efficacy and safety of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not have a clinical or virological benefit in the studied population.
14 wrz 2021 · Here we report the results of the DisCoVeRy trial comparing remdesivir to control in hospitalised patients with COVID-19. Remdesivir administration was well tolerated but was neither associated with a better clinical outcome at day 15 and 29 nor with a faster viral clearance.
22 maj 2020 · We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
16 lut 2022 · The early use of remdesivir in outpatients with Covid-19 who are at high risk for disease progression reduces the risk of hospitalization and death, as reported in our double-blind,...
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
